Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features - Takeaways - MDSpire

Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features

  • By

  • Yi Ruan

  • Hui Yuan

  • Feng Zheng

  • Xuehua Chen

  • Cheng Xu

  • June 23, 2026

  • 0 min

Share

  • 1

    The study aims to develop a radiomics-based predictive model for evaluating cervical lymph node response to 131I therapy in differentiated thyroid cancer.

  • 2

    Patients were stratified into Excellent and Non-Excellent response groups based on biochemical, imaging, and follow-up outcomes after 131I therapy.

  • 3

    Key inflammatory-related targets were identified from the GSE33630 dataset, and radiomics features were extracted from pre-therapeutic CT images.

  • 4

    The integrated clinical-radiomics model showed favorable discrimination, calibration, and clinical utility in predicting treatment response.

  • 5

    External validation and comparison with existing predictive strategies are necessary before the model can be routinely adopted in clinical practice.

Original Source(s)

Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features

  • by Yi Ruan, Hui Yuan, Feng Zheng, Xuehua Chen, Cheng Xu

  • June 23, 2026

Related Content

Ultrasound-guided, nursing-led, phase-based swallowing rehabilitation in elderly patients with MIBG-positive medullary thyroid carcinoma following 131I-MIBG therapy

Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies

Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma